论文部分内容阅读
应用免疫组化ＬＳＡＢ法，对３２例子宫内膜癌，６例腺瘤型增生，２０例腺囊型增生组织的癌基因Ｐ２１ｒａｓ、ｃ－ｍｙｃ及抑癌基因ｐ５３蛋白表达进行了检测，对３２例子宫内膜癌进行了雌、孕激素受体的检测，并对子宫内膜癌组织Ｐ２１ｒａｓ、ｃ－ｍｙｃ、ｐ５３过度表达与雌、孕激素受体的关系作了分析。结果显示：Ｐ２１ｒａｓ、ｃ－ｍｙｃ、ｐ５３在子宫内膜癌组织中的阳性表达率分别为５９．４％、６２．５％和１８．８％；雌、孕激素受体的阳性率分别为７５．０％、７１．９％，Ｐ２１ｒａｓ阳性表达与组织分化及术后生存期有关；ｃ－ｍｙｃ阳性表达与子宫内膜癌患者临床预后无关；ｐ５３ｒａｓ阳性表达与组织学类型、组织分化程度及术后生存期有关，与孕激素受体呈负相关。Ｐ２１ｒａｓ阳性表达预示患者预后较好，突变型ｐ５３蛋白的出现与子宫内膜癌的恶性生物学行为有关。
The expressions of oncogene P21ras, c-myc and p53 gene in 32 cases of endometrial carcinoma, 6 cases of adenomatous hyperplasia and 20 cases of cystic hyperplasia tissues were detected by immunohistochemical LSAB method. Cases of endometrial cancer were detected estrogen and progesterone receptors, and the endometrial cancer P21ras, c-myc, p53 overexpression and estrogen and progesterone receptors were analyzed. The results showed that the positive rates of P21ras, c-myc and p53 in endometrial carcinoma were 59.4%, 62.5% and 18.8% respectively. The positive rates of estrogen and progesterone receptor were 75 .0%, 71.9%, P21ras positive expression and tissue differentiation and postoperative survival; c-myc positive expression and endometrial cancer patients with no clinical prognosis; p53ras positive expression and histological type, degree of differentiation and surgery Post-survival, negative correlation with progesterone receptor. The positive expression of P21ras indicates the prognosis of patients is better, and the appearance of mutant p53 protein is associated with the malignant biological behavior of endometrial cancer.